Meta description: Mediar Therapeutics raises $76 million in Series B funding to push multiple anti-fibrotic drug candidates through Phase IIa trials, boosting total capital to $175 million.
Mediar Therapeutics has completed a $76 million oversubscribed Series B funding round to accelerate the clinical development of its fibrosis drug candidates. The financing brings the company’s total capital raised to approximately $175 million. This development is significant for investors, biotech founders, and stakeholders in pharmaceutical research targeting high unmet medical needs.
Who invested in this Series B round?
The Series B was co-led by ICG Life Sciences and Amplitude Ventures. Other new participants included Longwood Fund, Asahi Kasei Pharma Ventures, and Alexandria Real Estate Equities. Existing Series A investors also took part, showcasing continued confidence in Mediar’s strategy.
The oversubscription indicates strong investor belief in the company’s technology and potential market impact. With this capital, Mediar gains financial stability to reach critical clinical milestones.
What does the funding mean for Mediar’s growth?
This injection of $76 million supplements earlier funding rounds, bringing total raised to about $175 million. The company plans to use the capital to advance multiple clinical programs targeting fibrotic diseases affecting organs such as lungs, skin, and kidneys.
Fibrotic diseases represent a major unmet need due to the scarcity of effective treatments. Mediar’s ability to progress toward trial readouts could position it competitively in the fibrosis biotech sector. The funding also creates room for strategic options as new data emerges, including potential public market entry or additional private raises.
Which drug candidates are being advanced?
Mediar’s leading program, MTX-474, is an antibody directed at EphrinB2, a regulator of myofibroblast activation. It is currently in a Phase IIa study for systemic sclerosis. The trial uses validated endpoints to measure treatment effects on skin thickness.
Another asset, MTX-463, targets Wnt1-inducible signaling pathway protein-1 (WISP1), implicated in fibrosis development. This candidate is being studied for idiopathic pulmonary fibrosis through a global collaboration with Eli Lilly, which paid Mediar $99 million upfront for worldwide rights.
Both candidates are positioned to address high-need patient populations, and successful outcomes could strengthen Mediar’s valuation and licensing opportunities.
FAQ
1. How much total capital has Mediar raised?
Approximately $175 million from Series A, Series B, and licensing transactions.
2. What stage are Mediar’s drug candidates in?
Both MTX-474 and MTX-463 are in Phase IIa clinical trials targeting fibrotic diseases.
3. Who are the key investors in the latest funding round?
ICG Life Sciences, Amplitude Ventures, Longwood Fund, Asahi Kasei Pharma Ventures, and Alexandria Real Estate Equities.
4. What are fibrotic diseases?
Conditions characterized by excessive fibrous tissue buildup in organs, leading to functional impairment and potential organ failure.
Key takeaways
Mediar’s $76 million Series B expands its funding base to $175 million, enabling advancement of two Phase IIa programs for high-impact fibrotic conditions. New and existing investors provide strong backing, setting the stage for potential strategic expansion once trial data is available.
Disclaimer
This content is for informational purposes only and should not be interpreted as financial advice.